An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma

Table 2

Operative and pathological characteristics of both groups.

Characteristics	Group I	Group II	P values
Tumor location (head/body/tail)	98/14	96/24	.ns
Tumor size (mm)	3.2±1.3	3.5±0.8	.ns
Serum CA199 (U/mL)	210.7±45.6	284.3±55.7	.ns
Types of surgery
Whipple*	65	59	.ns
PPPD*	35	41	.ns
Partial or total pancreatectomy	12	20	.ns
Pathological differentiation (well/moderate/poor/others)	12/74/23/3	14/76/25/5	.ns
TNM* staging (I/II/III-IV)	58/49/5	49/64/7	.ns
Surgery margins (R0/R1/R2)	95/17/0	96/24/0	.ns
Operative time (min)	615±180	635±210	.ns
Blood loss (mL)	1120±350	1240±430	.ns
Hospital stay (day)	11.5±4.3	12.3±3.5	.ns

∗Whipple: standard pancreatoduodenectomy. PPPD: pylorus-preserving pancreatic resection. T: tumor. N: lymph nodes. M: metastasis.